Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right track. Weight-management treatments are all the rage lately. According to Morgan Stanley, combined sales of injections that curb appetites and promote weight loss could reach an estimated $105 billion by 2030. Viking Therapeutics (VKTX 3.25%) is still a clinical-stage drugmaker that's developing an anti-obesity candidate called VK2735 that appears competitive with a similar drug the U. ...

FDA approval marks first and only subcutaneous anti-PD-(L)1 cancer immunotherapy SAN DIEGO, Sept. 12, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received U.S. Food and Drug Administration (FDA) approval for Tecentriq Hybreza™ (atezolizumab and hyaluronidase-tqjs) with Halozyme's ENHANZE® drug delivery technology. Tecentriq Hybreza™ can be injected subcutaneously in approximately 7 minutes compared to 30-60 minutes for standard intravenous (IV) inf ...

Roche (RHHBY) presented results of an early-stage study on its experimental obesity drug, CT-996, at the European Association for the Study of Diabetes annual meeting. CT-996 is an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity. However, shares of the company were down 6% on Sept. 11, post the presentation on concerns of side-effects from the investigational obesity drug. Image Source: Zacks Investment Research Ye ...

The company had a dispiriting update to offer about an investigational drug. For the second trading session in less than a week, Roche Holding (RHHBY -6.02%) stock really took it on the chin Wednesday. Dispiriting news about its investigational obesity drug was the culprit; disseminating this, investors sold out of the pharmaceutical veteran. At the end of the day's action, Roche had lost almost 6% of its value. Obesity drug disappoints In a meeting of the European Association for the Study of Diabetes that ...

10'000 Hours/DigitalVision via Getty Images Investment Overview I last covered the Swiss pharma giant Roche (OTCQX:RHHBY) in a note for Seeking Alpha in mid-May, giving the company's stock a "Buy" recommendation. Shares have risen in value by ~22% since, trading at ~$40 at the time of writing, which translates to a market cap valuation of $254bn. In that note I wrote: Roche has been struggling for top and bottom line growth over the past several years, and this may have affected its share price and valuatio ...

Lunit's AI-powered biomarker, Lunit SCOPE PD-L1 TPS, integrates into Roche's navify® Digital Pathology platform to enhance precision medicine and improve cancer biomarker testing SEOUL, South Korea, Sept. 9, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AIpowered solutions for cancer diagnostics and therapeutics, today announced its collaboration with Roche to integrate Lunit SCOPE PD-L1 22C3 TPS into Roche's navify® Digital Pathology platform. This marks the first deployment of Lunit's ...

For Immediate Releases Chicago, IL – September 9, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. (AMZN) , Roche Holding AG (RHHBY) , GE Aerospace (GE) , Canterbury Park Holding Corp. (CPHC) and NVE Corp. (NVEC) . Here are highlights from Monday's Analyst Blog: Top Analyst Reports for Amazon.com, ...

Stratipath, a global leader in artificial intelligence (AI)-based precision diagnostic solutions, is thrilled to announce a collaboration with Roche, the world's largest biotechnology company and the global leader in invitro diagnostics. In this non-exclusive collaboration, Roche will have the distribution rights to the integrated Stratipath solution, Stratipath Breast. The integration between Stratipath Breast and Roche's navify® Digital Pathology enterprise software enables Roche customers to seamlessly p ...

New Phase II data show vast majority of patients experiencing no relapses or disability progression Fenebrutinib suppressed acute and chronic MRI lesions Fenebrutinib's safety profile was consistent with previous and ongoing clinical trials across multiple diseases including more than 2,700 people to date Basel, 04 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new 48-week data for the investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib from the Phase II FENopta open-labe ...

With the option to self-administer, PiaSky® (crovalimab) has the potential to reduce treatment burden for people with paroxysmal nocturnal haemoglobinuria (PNH) in Europe and their caregivers Approval is based on COMMODORE 2, where subcutaneous (SC) PiaSky once a month was equivalent to intravenous eculizumab every two weeks1,2 PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration3 Basel, 27 August 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announc ...